- PR Newswire•7 days agoImmune Therapeutics, Inc., Through Its Wholly Owned Subsidiary TNI BioTech International, Ltd., Initiates Clinical Trial In Malawi With LDN For The Prevention Of Cervical Cancer
ORLANDO, Fla., Aug. 23, 2016 /PRNewswire/ -- Immune Therapeutics, Inc. (OTCQB-IMUN) ("IMUN"), headquartered in Orlando, Florida, is a clinical-stage biopharmaceutical company involved in the commercialization, manufacturing, distribution and marketing of its novel immunotherapies to combat chronic, life-threatening diseases through the activation and modulation of the body's immune system. IMUN, in conjunction with the College of Medicine Malawi, has initiated a clinical study with LDN for the prevention of cervical cancer. This is an open-label, multicenter study designed to determine the safety and acceptability of a single-visit approach to cervical cancer prevention in patients.
- Marketwired•last monthImmune Therapeutics, Inc. to Hold an Informational Shareholder Meeting on Wednesday, August 17, 2016 at 10 A.M. EDT
Immune Therapeutics, Inc. An Informational Shareholder Meeting will be held on Wednesday, August 17, 2016, at 10 a.m. EDT, at the Citrus Club, 255 South Orange Avenue, Suite 1800, Orlando, FL 32801.
- GlobeNewswire•2 months agoImmune Therapeutics, Inc. Announces Engagement of Maxim Group LLC to Provide Strategic Advisory Services
ORLANDO, Fla., June 15, 2016-- Immune Therapeutics, Inc., a clinical-stage biotech company providing immunotherapy solutions for the treatment of infectious and non-infectious diseases, today announced ...
Immune Therapeutics, Inc. (IMUN)
Other OTC - Other OTC Delayed Price. Currency in USD
|Day's Range||0.10 - 0.11|
|52wk Range||0.07 - 0.36|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-1.03|
|Avg Vol (3m)||276,404|
|Dividend & Yield||N/A (N/A)|